Michael P Barrett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2130046/publications.pdf

Version: 2024-02-01

155 papers	9,410 citations	38742 50 h-index	46799 89 g-index
166 all docs	166 docs citations	166 times ranked	9899 citing authors

#	Article	IF	Citations
1	The Knock-Down of the Chloroquine Resistance Transporter PfCRT Is Linked to Oligopeptide Handling in Plasmodium falciparum. Microbiology Spectrum, 2022, 10, .	3.0	11
2	Mammalian Deubiquitinating Enzyme Inhibitors Display in Vitro and in Vivo Activity against Malaria Parasites and Potentiate Artemisinin Action. ACS Infectious Diseases, 2021, 7, 333-346.	3.8	8
3	Truncated S-MGBs: towards a parasite-specific and low aggregation chemotype. RSC Medicinal Chemistry, 2021, 12, 1391-1401.	3.9	2
4	Procyclic trypanosomes recycle glucose catabolites and TCA cycle intermediates to stimulate growth in the presence of physiological amounts of proline. PLoS Pathogens, 2021, 17, e1009204.	4.7	16
5	A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 2021, 7, 21.	7.0	14
6	Diminazene resistance in Trypanosoma congolense is not caused by reduced transport capacity but associated with reduced mitochondrial membrane potential. Molecular Microbiology, 2021, 116, 564-588.	2.5	14
7	Plasmodium falciparum LipB mutants display altered redox and carbon metabolism in asexual stages and cannot complete sporogony in Anopheles mosquitoes. International Journal for Parasitology, 2021, 51, 441-453.	3.1	9
8	Divergent metabolism between Trypanosoma congolense and Trypanosoma brucei results in differential sensitivity to metabolic inhibition. PLoS Pathogens, 2021, 17, e1009734.	4.7	11
9	Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis. Trends in Parasitology, 2021, 37, 831-843.	3.3	17
10	Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the Leishmania Inositol Phosphorylceramide Synthase. ACS Infectious Diseases, 2021, 7, 47-63.	3.8	15
11	Transcriptional differentiation of Trypanosoma brucei during in vitro acquisition of resistance to acoziborole. PLoS Neglected Tropical Diseases, 2021, 15, e0009939.	3.0	2
12	New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infectious Diseases, The, 2020, 20, e38-e46.	9.1	90
13	Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. Nature Microbiology, 2020, 5, 1207-1216.	13.3	45
14	Running on Empty: A Metabolomics Approach to Investigating Changing Energy Metabolism during Fasted Exercise and Rest. Metabolites, 2020, 10, 399.	2.9	7
15	Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes. Journal of Biological Chemistry, 2020, 295, 8331-8347.	3.4	32
16	Cell-based and multi-omics profiling reveals dynamic metabolic repurposing of mitochondria to drive developmental progression of Trypanosoma brucei. PLoS Biology, 2020, 18, e3000741.	5.6	32
17	New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story. Tropical Medicine and Infectious Disease, 2020, 5, 29.	2.3	83
18	Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis. Tropical Medicine and Infectious Disease, 2020, 5, 28.	2.3	8

#	Article	IF	Citations
19	Experimentally Engineered Mutations in a Ubiquitin Hydrolase, UBP-1, Modulate In Vivo Susceptibility to Artemisinin and Chloroquine in Plasmodium berghei. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	18
20	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathogens, 2020, 16, e1008932.	4.7	16
21	Halogenated tryptophan derivatives disrupt essential transamination mechanisms in bloodstream form Trypanosoma brucei. PLoS Neglected Tropical Diseases, 2020, 14, e0008928.	3.0	6
22	In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei. Methods in Molecular Biology, 2020, 2116, 801-817.	0.9	3
23	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
24	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
25	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
26	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
27	Protozoan persister-like cells and drug treatment failure. Nature Reviews Microbiology, 2019, 17, 607-620.	28.6	97
28	Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites. PLoS Neglected Tropical Diseases, 2019, 13, e0007052.	3.0	39
29	Mapping the metabolism of five amino acids in bloodstream form Trypanosoma brucei using U-13C-labelled substrates and LCâ€“MS. Bioscience Reports, 2019, 39, .	2.4	17
30	Novel Minor Groove Binders Cure Animal African Trypanosomiasis in an in Vivo Mouse Model. Journal of Medicinal Chemistry, 2019, 62, 3021-3035.	6.4	18
31	Small Polar Hits against S. aureus: Screening, Initial Hit Optimization, and Metabolomic Studies. ACS Omega, 2019, 4, 19199-19215.	3.5	2
32	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	3.8	78
33	Untargeted metabolomics to understand the basis of phenotypic differences in amphotericin B-resistant Leishmania parasites. Wellcome Open Research, 2019, 4, 176.	1.8	10
34	Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
35	Metabolic Clustering Analysis as a Strategy for Compound Selection in the Drug Discovery Pipeline for Leishmaniasis. ACS Chemical Biology, 2018, 13, 1361-1369.	3.4	15
36	Gluconeogenesis using glycerol as a substrate in bloodstream-form Trypanosoma brucei. PLoS Pathogens, 2018, 14, e1007475.	4.7	32

#	Article	IF	Citations
37	The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. PLoS Neglected Tropical Diseases, 2018, 12, e0006925.	3.0	45
38	The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing. PLoS Pathogens, 2018, 14, e1007315.	4.7	53
39	An integrated portable system for single chip simultaneous measurement of multiple disease associated metabolites. Biosensors and Bioelectronics, 2018, 122, 88-94.	10.1	12
40	Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. PLoS Neglected Tropical Diseases, 2018, 12, e0006450.	3.0	33
41	Metabolomic profiling of macrophages determines the discrete metabolomic signature and metabolomic interactome triggered by polarising immune stimuli. PLoS ONE, 2018, 13, e0194126.	2.5	35
42	Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathogens, 2018, 14, e1006850.	4.7	26
43	Deletion of transketolase triggers a stringent metabolic response in promastigotes and loss of virulence in amastigotes of Leishmania mexicana. PLoS Pathogens, 2018, 14, e1006953.	4.7	18
44	Functional and genetic evidence that nucleoside transport is highly conserved in Leishmania species: Implications for pyrimidine-based chemotherapy. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 206-226.	3.4	32
45	Inside Doctor Livingstone: a Scottish icon's encounter with tropical disease. Parasitology, 2017, 144, 1652-1662.	1.5	1
46	Microfluidics-Based Approaches to the Isolation of African Trypanosomes. Pathogens, 2017, 6, 47.	2.8	6
47	Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Neglected Tropical Diseases, 2017, 11, e0006052.	3.0	571
48	Antileishmanial and antitrypanosomal drug identification. Emerging Topics in Life Sciences, 2017, 1, 613-620.	2.6	5
49	Sterol 14Î±-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana. PLoS Neglected Tropical Diseases, 2017, 11, e0005649.	3.0	43
50	Evaluation of Antigens for Development of a Serological Test for Human African Trypanosomiasis. PLoS ONE, 2016, 11, e0168074.	2.5	12
51	Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation. Metabolomics, 2016, 12, 125.	3.0	30
52	The animal trypanosomiases and their chemotherapy: a review. Parasitology, 2016, 143, 1862-1889.	1.5	308
53	The Pentose Phosphate Pathway in Parasitic Trypanosomatids. Trends in Parasitology, 2016, 32, 622-634.	3.3	62
54	Untargeted Metabolomics To Ascertain Antibiotic Modes of Action. Antimicrobial Agents and Chemotherapy, 2016, 60, 2281-2291.	3.2	78

#	Article	IF	Citations
55	Metabolomics Identifies Multiple Candidate Biomarkers to Diagnose and Stage Human African Trypanosomiasis. PLoS Neglected Tropical Diseases, 2016, 10, e0005140.	3.0	74
56	Stage-Specific Changes in Plasmodium Metabolism Required for Differentiation and Adaptation to Different Host and Vector Environments. PLoS Pathogens, 2016, 12, e1006094.	4.7	82
57	Host Reticulocytes Provide Metabolic Reservoirs That Can Be Exploited by Malaria Parasites. PLoS Pathogens, 2015, 11, e1004882.	4.7	67
58	Crystal Structure of an Arginase-like Protein from Trypanosoma brucei That Evolved without a Binuclear Manganese Cluster. Biochemistry, 2015, 54, 458-471.	2.5	26
59	Potent Trypanocidal Curcumin Analogs Bearing a Monoenone Linker Motif Act on Trypanosoma brucei by Forming an Adduct with Trypanothione. Molecular Pharmacology, 2015, 87, 451-464.	2.3	24
60	Bestatin Induces Specific Changes in Trypanosoma cruzi Dipeptide Pool. Antimicrobial Agents and Chemotherapy, 2015, 59, 2921-2925.	3.2	8
61	Intravital Imaging of a Massive Lymphocyte Response in the Cortical Dura of Mice after Peripheral Infection by Trypanosomes. PLoS Neglected Tropical Diseases, 2015, 9, e0003714.	3.0	31
62	An Atypical Mitochondrial Carrier That Mediates Drug Action in Trypanosoma brucei. PLoS Pathogens, 2015, 11, e1004875.	4.7	15
63	Probing the Metabolic Network in Bloodstream-Form Trypanosoma brucei Using Untargeted Metabolomics with Stable Isotope Labelled Glucose. PLoS Pathogens, 2015, 11, e1004689.	4.7	128
64	Vacuolar ATPase depletion affects mitochondrial ATPase function, kinetoplast dependency, and drug sensitivity in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9112-9117.	7.1	39
65	LCâ€“MS-based absolute metabolite quantification: application to metabolic flux measurement in trypanosomes. Metabolomics, 2015, 11, 1721-1732.	3.0	36
66	TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. Nucleic Acids Research, 2015, 43, D637-D644.	14.5	35
67	Metabolomic-Based Strategies for Anti-Parasite Drug Discovery. Journal of Biomolecular Screening, 2015, 20, 44-55.	2.6	46
68	Characterization of a Melamino Nitroheterocycle as a Potential Lead for the Treatment of Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5747-5757.	3.2	2
69	Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics. PLoS Neglected Tropical Diseases, 2014, 8, e2844.	3.0	90
70	BCKDH: The Missing Link in Apicomplexan Mitochondrial Metabolism Is Required for Full Virulence of Toxoplasma gondii and Plasmodium berghei. PLoS Pathogens, 2014, 10, e1004263.	4.7	115
71	Rareâ€Cell Enrichment by a Rapid, Labelâ€Free, Ultrasonic Isopycnic Technique for Medical Diagnostics. Angewandte Chemie - International Edition, 2014, 53, 5587-5590.	13.8	51
72	Determination of antiprotozoal drug mechanisms by metabolomics approaches. Parasitology, 2014, 141, 83-92.	1.5	47

#	Article	IF	Citations
73	Emerging paradigms in anti-infective drug design. Parasitology, 2014, 141, 1-7.	1.5	24
74	The Silicon Trypanosome. Advances in Microbial Physiology, 2014, 64, 115-143.	2.4	5
75	Trypanosoma brucei: meet the system. Current Opinion in Microbiology, 2014, 20, 162-169.	5.1	10
76	Advances in Understanding and Treatment of Human African Trypanosomiasis: Divergent Diseases Caused by Distinct Parasites. , 2014, , 901-917.		4
77	Rareâ€Cell Enrichment by a Rapid, Labelâ€Free, Ultrasonic Isopycnic Technique for Medical Diagnostics. Angewandte Chemie, 2014, 126, 5693-5696.	2.0	11
78	Shapeâ€Dependent Optoelectronic Cell Lysis. Angewandte Chemie - International Edition, 2014, 53, 842-846.	13.8	17
79	The threonine degradation pathway of the <scp>T</scp>rypanosoma brucei procyclic form: the main carbon source for lipid biosynthesis is under metabolic control. Molecular Microbiology, 2013, 90, 114-129.	2.5	58
80	Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. International Journal for Parasitology: Drugs and Drug Resistance, 2013, 3, 69-76.	3.4	57
81	Minor groove binders as anti-infective agents. , 2013, 139, 12-23.		73
82	In Vivo Imaging of Trypanosome-Brain Interactions and Development of a Rapid Screening Test for Drugs against CNS Stage Trypanosomiasis. PLoS Neglected Tropical Diseases, 2013, 7, e2384.	3.0	59
83	A Trypanosoma brucei Kinesin Heavy Chain Promotes Parasite Growth by Triggering Host Arginase Activity. PLoS Pathogens, 2013, 9, e1003731.	4.7	48
84	mzMatchâ€“ISO: an R tool for the annotation and relative quantification of isotope-labelled mass spectrometry data. Bioinformatics, 2013, 29, 281-283.	4.1	91
85	Handling Uncertainty in Dynamic Models: The Pentose Phosphate Pathway in Trypanosoma brucei. PLoS Computational Biology, 2013, 9, e1003371.	3.2	40
86	Metabolomics Guides Rational Development of a Simplified Cell Culture Medium for Drug Screening against Trypanosoma brucei. Antimicrobial Agents and Chemotherapy, 2013, 57, 2768-2779.	3.2	88
87	Explicit consideration of topological and parameter uncertainty gives new insights into a wellâ€established model of glycolysis. FEBS Journal, 2013, 280, 4640-4651.	4.7	15
88	Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei. PLoS Neglected Tropical Diseases, 2012, 6, e1618.	3.0	101
89	Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10996-11001.	7.1	134
90	Management of trypanosomiasis and leishmaniasis. British Medical Bulletin, 2012, 104, 175-196.	6.9	240

#	Article	IF	Citations
91	Counterflow Dielectrophoresis for Trypanosome Enrichment and Detection in Blood. Scientific Reports, 2012, 2, 775.	3.3	23
92	IDEOM: an Excel interface for analysis of LCâ€“MS-based metabolomics data. Bioinformatics, 2012, 28, 1048-1049.	4.1	307
93	Synthesis and Biological Evaluation of CTP Synthetase Inhibitors as Potential Agents for the Treatment of African Trypanosomiasis. ChemMedChem, 2012, 7, 1623-1634.	3.2	29
94	Stable Isotope-Assisted Metabolomics for Network-Wide Metabolic Pathway Elucidation. Analytical Chemistry, 2012, 84, 8442-8447.	6.5	132
95	Dynamic Modelling under Uncertainty: The Case of Trypanosoma brucei Energy Metabolism. PLoS Computational Biology, 2012, 8, e1002352.	3.2	28
96	Metabolomic analysis of trypanosomatid protozoa. Molecular and Biochemical Parasitology, 2012, 181, 73-84.	1.1	54
97	Multiple roles of proline transport and metabolism in trypanosomatids. Frontiers in Bioscience - Landmark, 2012, 17, 349.	3.0	38
98	The Diamidine Diminazene Aceturate Is a Substrate for the High-Affinity Pentamidine Transporter: Implications for the Development of High Resistance Levels in Trypanosomes. Molecular Pharmacology, 2011, 80, 110-116.	2.3	37
99	Drug resistance in human African trypanosomiasis. Future Microbiology, 2011, 6, 1037-1047.	2.0	121
100	Development of novel drugs for human African trypanosomiasis. Future Microbiology, 2011, 6, 677-691.	2.0	120
101	Toward Global Metabolomics Analysis with Hydrophilic Interaction Liquid Chromatographyâ€“Mass Spectrometry: Improved Metabolite Identification by Retention Time Prediction. Analytical Chemistry, 2011, 83, 8703-8710.	6.5	326
102	Separation of parasites from human blood using deterministic lateral displacement. Lab on A Chip, 2011, 11, 1326.	6.0	180
103	Transketolase in Trypanosoma brucei. Molecular and Biochemical Parasitology, 2011, 179, 1-7.	1.1	23
104	Pathos: A web facility that uses metabolic maps to display experimental changes in metabolites identified by mass spectrometry. Rapid Communications in Mass Spectrometry, 2011, 25, 3422-3426.	1.5	49
105	Semiâ€targeted analysis of metabolites using capillaryâ€flow ion chromatography coupled to highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2011, 25, 3447-3452.	1.5	59
106	Synthesis and inâ€...vitro/inâ€...vivo Evaluation of the Antitrypanosomal Activity of 3â€Bromoacivicin, a Potent CTP Synthetase Inhibitor. ChemMedChem, 2011, 6, 329-333.	3.2	33
107	Trypanocidal Furamidine Analogues: Influence of Pyridine Nitrogens on Trypanocidal Activity, Transport Kinetics, and Resistance Patterns. Antimicrobial Agents and Chemotherapy, 2011, 55, 2352-2361.	3.2	49
108	Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis. PLoS Neglected Tropical Diseases, 2011, 5, e1308.	3.0	51

#	Article	IF	Citations
109	Metabolomic systems biology of trypanosomes. Parasitology, 2010, 137, 1285-1290.	1.5	19
110	Potential new drugs for human African trypanosomiasis: some progress at last. Current Opinion in Infectious Diseases, 2010, 23, 603-608.	3.1	51
111	Use of reconstituted metabolic networks to assist in metabolomic data visualization and mining. Metabolomics, 2010, 6, 312-321.	3.0	29
112	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorganic and Medicinal Chemistry, 2010, 18, 5056-5062.	3.0	26
113	MetExplore: a web server to link metabolomic experiments and genome-scale metabolic networks. Nucleic Acids Research, 2010, 38, W132-W137.	14.5	148
114	Multiple Genetic Mechanisms Lead to Loss of Functional TbAT1 Expression in Drug-Resistant Trypanosomes. Eukaryotic Cell, 2010, 9, 336-343.	3.4	30
115	A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes. PLoS Pathogens, 2010, 6, e1001204.	4.7	155
116	The silicon trypanosome. Parasitology, 2010, 137, 1333-1341.	1.5	25
117	The 6-Phosphogluconate Dehydrogenase of Leishmania (Leishmania) mexicana: Gene Characterization and Protein Structure Prediction. Journal of Molecular Microbiology and Biotechnology, 2010, 19, 213-223.	1.0	8
118	Diamidines for human African trypanosomiasis. Current Opinion in Investigational Drugs, 2010, 11, 876-83.	2.3	61
119	Genotypic Status of the TbAT1/P2 Adenosine Transporter of Trypanosoma brucei gambiense Isolates from Northwestern Uganda following Melarsoprol Withdrawal. PLoS Neglected Tropical Diseases, 2009, 3, e523.	3.0	16
120	New surveyor tools for charting microbial metabolic maps. Nature Reviews Microbiology, 2008, 6, 156-161.	28.6	83
121	A new erythrose 4-phosphate dehydrogenase coupled assay for transketolase. Journal of Proteomics, 2008, 70, 1185-1187.	2.4	9
122	Glucose-induced Remodeling of Intermediary and Energy Metabolism in Procyclic Trypanosoma brucei. Journal of Biological Chemistry, 2008, 283, 16342-16354.	3.4	113
123	Synthesis and Biological Evaluation of Phosphate Prodrugs of 4â€Phosphoâ€<scp>D</scp> â€erythronohydroxamic Acid, an Inhibitor of 6â€Phosphogluconate Dehydrogenase. ChemMedChem, 2007, 2, 1169-1180.	3.2	27
124	McArthur revisited: fluorescence microscopes for field diagnostics. Trends in Parasitology, 2007, 23, 468-469.	3.3	16
125	Targeting of Toxic Compounds to the Trypanosome's Interior. Advances in Parasitology, 2006, 63, 125-183.	3.2	52
126	The rise and fall of sleeping sickness. Lancet, The, 2006, 367, 1377-1378.	13.7	75

#	Article	IF	Citations
127	Ab initio prediction of metabolic networks using Fourier transform mass spectrometry data. Metabolomics, 2006, 2, 155-164.	3.0	117
128	Precision mapping of the metabolome. Trends in Biotechnology, 2006, 24, 543-548.	9.3	125
129	Roles for theTrypanosoma bruceiP2 Transporter in DB75 Uptake and Resistance. Molecular Pharmacology, 2006, 70, 1585-1592.	2.3	54
130	Energy generation in insect stages of Trypanosoma brucei: metabolism in flux. Trends in Parasitology, 2005, 21, 185-191.	3.3	112
131	Proline Metabolism in Procyclic Trypanosoma brucei Is Down-regulated in the Presence of Glucose. Journal of Biological Chemistry, 2005, 280, 11902-11910.	3.4	190
132	Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet, The, 2005, 366, 486-487.	13.7	46
133	Design and Synthesis of a Series of Melamine-based Nitroheterocycles with Activity against Trypanosomatid Parasites. Journal of Medicinal Chemistry, 2005, 48, 5570-5579.	6.4	153
134	Selective Inhibition of Trypanosoma brucei 6-Phosphogluconate Dehydrogenase by High-Energy Intermediate and Transition-State Analogues. Journal of Medicinal Chemistry, 2004, 47, 3427-3437.	6.4	33
135	Transketolase from Leishmania mexicana has a dual subcellular localization. Biochemical Journal, 2004, 382, 759-767.	3.7	47
136	Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in Parasitology, 2003, 19, 232-239.	3.3	208
137	Pentose phosphate metabolism in Leishmania mexicana. Molecular and Biochemical Parasitology, 2003, 130, 117-125.	1.1	72
138	Synthesis and biological evaluation of substrate-Based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African Trypanosomiasis. Bioorganic and Medicinal Chemistry, 2003, 11, 3205-3214.	3.0	27
139	The trypanosomiases. Lancet, The, 2003, 362, 1469-1480.	13.7	673
140	Mechanisms of Arsenical and Diamidine Uptake and Resistance in Trypanosoma brucei. Eukaryotic Cell, 2003, 2, 1003-1008.	3.4	186
141	Genetic characterization of glucose transporter function in Leishmania mexicana. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3901-3906.	7.1	124
142	Activity of Megazol, a Trypanocidal Nitroimidazole, Is Associated with DNA Damage. Antimicrobial Agents and Chemotherapy, 2003, 47, 3368-3370.	3.2	54
143	Perspectives for New Drugs Against Trypanosomiasis and Leishmaniasis. Current Topics in Medicinal Chemistry, 2002, 2, 471-482.	2.1	48
144	Polymorphism among alleles of the 6-Phosphogluconate dehydrogenase gene from Leishmania major and Leishmania tropica. Molecular and Biochemical Parasitology, 2002, 125, 185-188.	1.1	10

#	Article	IF	Citations
145	Uptake and mode of action of drugs used against sleeping sickness. Biochemical Pharmacology, 2001, 61, 1-5.	4.4	72
146	The structure-function relationship of functionally distinct but structurally similar hexose transporters from Trypanosoma congolense. FEBS Journal, 2000, 267, 4850-4860.	0.2	7
147	Transport of methionine in Trypanosoma brucei brucei. Molecular and Biochemical Parasitology, 2000, 111, 299-307.	1.1	18
148	Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochemical Pharmacology, 2000, 59, 615-620.	4.4	27
149	6-Phosphogluconate dehydrogenase from Lactococcus lactis: a role for arginine residues in binding substrate and coenzyme. Biochemical Journal, 1999, 338, 55-60.	3.7	27
150	Trypanosome glucose transporters. Molecular and Biochemical Parasitology, 1998, 91, 195-205.	1.1	62
151	Emerging therapeutic targets in parasitic protozoa. Expert Opinion on Therapeutic Targets, 1998, 2, 57-85.	1.0	1
152	A 2.8 Ã... resolution structure of 6-phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei : comparison with the sheep enzyme accounts for differences in activity with coenzyme and substrate analogues 1 1Edited by R. Huber. Journal of Molecular Biology, 1998, 282, 667-681.	4.2	58
153	6-Phosphogluconate Dehydrogenase from Trypanosoma Brucei. Kinetic Analysis and Inhibition by Trypanocidal Drugs. FEBS Journal, 1996, 240, 592-599.	0.2	44
154	Hypervariability in Gene Copy Number for the Glucose Transporter Genes in Trypanosomes. Journal of Eukaryotic Microbiology, 1996, 43, 244-249.	1.7	4
155	A 6-phosphogluconate dehydrogenase gene from Trypanosoma brucei. Molecular and Biochemical Parasitology, 1993, 57, 89-99.	1.1	30